logo

CRVO

CervoMed·NASDAQ
--
--(--)
--
--(--)
3.34 / 10
Netural

CRVO's financial evaluation is weak, scoring only 3.3/10. Key concerns include suboptimal Asset-MV (-0.5066) and PB-ROE (1.2503) metrics, placing them in low-performing quartiles. Conversely, strong Gross Profit Margin (100%) and Inventory Turnover (47.88) offer some relief. Overall, the fundamental picture is constrained, warranting caution.

Fundamental(3.34)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-3.81
Score2/3
Weight18.74%
1M Return11.31%
Inventory turnover ratio
Value47.88
Score3/3
Weight8.45%
1M Return5.89%
Gross profit margin (%)
Value100.00
Score3/3
Weight18.70%
1M Return11.05%
Profit-MV
Value0.47
Score2/3
Weight12.91%
1M Return7.95%
Net income-Revenue
Value-0.15
Score2/3
Weight13.09%
1M Return8.04%
PB-ROE
Value1.25
Score0/3
Weight6.62%
1M Return4.05%
Current assets turnover ratio
Value0.11
Score1/3
Weight0.36%
1M Return0.27%
Fixed assets turnover ratio
Value7993.84
Score3/3
Weight1.95%
1M Return1.53%
Asset-MV
Value-0.51
Score0/3
Weight6.38%
1M Return4.17%
Cash-MV
Value-0.07
Score2/3
Weight12.79%
1M Return7.78%
Is CRVO fundamentally strong?
  • CRVO scores 3.34/10 on fundamentals and holds a Fair valuation at present. Backed by its -57.90% ROE, -415.36% net margin, -1.92 P/E ratio, 1.89 P/B ratio, and -33.64% earnings growth, these metrics solidify its Netural investment rating.